According to Singular Genomics Systems's latest financial reports the company has $0.17 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2022-12-31 | $0.24 B | -27.9% |
2021-12-31 | $0.33 B | 1160.16% |
2020-12-31 | $26.91 M | -41.73% |
2019-12-31 | $46.19 M |